Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham PlcfiledCriticalSmithkline Beecham Plc
Publication of MA26758A1publicationCriticalpatent/MA26758A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
"Composition nouvelle, à libération modifiée, pour le traitement du diabète" L'invention concerne une composition pharmaceutique à libération modifiée. Cette composition comprend un sensibilisant à l'insuline, un autre agent antidiabétique et un support pharmaceutiquement acceptable. Application : utilisation de cette composition pour le traitement du diabète."Novel, modified-release composition for the treatment of diabetes" The invention relates to a modified-release pharmaceutical composition. This composition includes an insulin sensitizer, another anti-diabetic agent and a pharmaceutically acceptable carrier. Application: use of this composition for the treatment of diabetes.
MA26192A1998-11-122001-05-11
NEW, MODIFIED RELEASE COMPOSITION FOR THE TREATMENT OF DIABETES.
MA26758A1
(en)
(1S, 2S) -1- (4-HYDROXYPHENYL) -2- (4-HYDROXY-4-PHENYLPIPERIDINE-1-YL) -1-PROPANOL TRIHYDRATE METAHENSULFONATE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND ITS UTILIZATION IN THE TREATMENT OF RELATED DIABETES AND DISEASES
Compound, pharmaceutical composition, use of, a compound and methods for the treatment of diabetic complications, for the treatment or prevention of the development of disease conditions associated with impaired neuronal conduction velocity and diabetic neuropathy